Active Biotech AB Interim report January - June 2016
August 11 2016 - 2:35AM
LUND, Sweden, Aug. 11, 2016 (GLOBE NEWSWIRE) --
Laquinimod
- The clinical trials CONCERTO, ARPEGGIO and LEGATO-HD are
progressing according to plan
- The study results from both the pivotal clinical Phase 3
CONCERTO trial in relapsing remitting multiple sclerosis (RRMS) and
the Phase 2 study ARPEGGIO, evaluating laquinimod for the treatment
of primary progressive multiple sclerosis (PPMS), are expected in
the first half of 2017
- Positive results concerning laquinimod were presented at the
68th AAN Annual Meeting (American Academy of Neurology), held in
Vancouver, Canada, on April 15-21, 2016
Tasquinimod
- The complete study results of the Phase 3 10TASQ10 study have
been published in the Journal of Clinical Oncology
- Out-licensing activities are continuing
ANYARA, Paquinimod (57-57) and SILC (ISI)
- Out-licensing activities are continuing
Financial summary
SEK
M |
Q2 |
Q1-Q2 |
Full Year |
|
2016 |
2015 |
2016 |
2015 |
2015 |
|
|
|
|
|
|
Net sales |
3.9 |
3.2 |
7.9 |
6.1 |
16.3 |
Operating loss |
-14.5 |
-70.1 |
-30.6 |
-127.5 |
-177.9 |
Loss for the period |
-15.5 |
-71.4 |
-32.3 |
-129.3 |
-193.5 |
Loss per share, before and
after dilution (SEK) |
-0.17 |
-0.79 |
-0.36 |
-1.44 |
-2.15 |
Cash and cash equivalents
(at the end of the period) |
|
|
57.4 |
186.6 |
103.6 |
- Refocusing of the company is completed, operating costs reduced
by 71% (SEK 95.2 M) compared with 2015
- The number of employees will be reduced from 56 (June 2015) to
17 by the end of the third quarter of 2016
- Operations are progressing according to plan pending the Phase
3 results for laquinimod in the first half of 2017
For further information, please
contact:
Tomas Leanderson, President and CEO
Tel: +46 46 19 20 95 Hans Kolam, CFO Tel: +46
46 19 20 44 |
Active Biotech AB (Corp.
Reg. No. 556223-9227) Box 724, SE-220 07 Lund Tel: +46 46 19 20 00
Fax: +46 46 19 11 05 |
The report is also available at
www.activebiotech.com.
Active Biotech AB (publ) Interim Report January - June 2016
http://hugin.info/1002/R/2034058/757619.pdf
HUG#2034058
Actividentity Corp (MM) (NASDAQ:ACTI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Actividentity Corp (MM) (NASDAQ:ACTI)
Historical Stock Chart
From Apr 2023 to Apr 2024